GLG News by General Cardiologists (US)

Given that obesity is one of the prime causes of type II diabetes, and that an important part of the patient's treatment should be directed to weight loss which improves insulin resistance, I feel that prescribing drugs that you know will cause the patient to fail at losing weight are counterproductive. ...

Resveratrol might indeed be a block buster compound due to a variety of its properties the lease of which might be its powerful antioxidant properties. This compound probably best explains the FRENCH PARADOX, which is that despite the consumption of high fat dense caloric food consumed by rich French...

Factor IX is also a promising target, as it is unique in carrying the coagulation signal from the site of injury with tissue factor activation, to the surface of platelets, where propagation and amplification of coagulation actually occur. REG1 (Regado Biosciences), a highly specific, actively reversible...

ExForge is a product that we in the hypertension business are very anxious to have available. Combination tablets have been increasing in sales very dramatically in the past few years and will soon overtake, in my opinion, single agents. Lotrel led the way toward combinations that do not include a diuretic...

Newly introduced guidelines for treatment targets in hypertensive patients target lower blood pressures than  those previously suggested by JNC.  Since it has already been demonstrated that control of BP to current targets in many hypertensives requires three or more drugs, even lower targets...

Initial study design noninferiority Revised statistics superiority Trial showed equivalent results for treatment response But did not meet criteria for superiority Similar performance for induction is suggested But we await the results of maintenance phase (more important)

Peripheral lung nodules have been difficult for the bronchoscopist in the past to biopsy in order to identify the etiology. Using these two techniques, which requires some increased training by the interventionalist, the bronchoscopist may be able to now diagnose malignancy vs infection to help with...

This class of drug has had issues in the past, and while the study is interesting, a Phase 1b trial is hardly earth shattering.  Wait for the clinical event trials that the FDA will definitely require especially in the aftermath of Torsetrapib.

Like all combo drugs, many IM's will love it, as it is convenient.  Cardiologists hate combo drugs except htn meds in combination with HCTZ.  (eg lotrel, which no cardiologist has ever given).  This is another desparate attempt on Pfizer's behalf to keep branded norvasc alive. &...

Gee whiz, so Cephalon had isolated the enantiomer of provigil that is effetcive. This is the equivalent to AZ isoloating the s enantiomer of ompeprazole to create Nexium and lord ir over prilosec. This is no great feat chemically or pharmacologiclly. What it may mean is millions in profits for investors....